Initially launching in Germany, the app will soon be available in the UK, Australia, Canada, and other markets.

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

One of the most agonizing experiences a cancer patient suffers is waiting without knowing: waiting for a diagnosis, waiting ...

Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

ScreenPoint Medical found that its Transpara AI tool increased cancer detection by 29% and reduced radiologist read times by ...

The MASAI trial reveals AI in mammography increases cancer detection by 29% and decreases radiologists' workload by 44%, ...

Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in ...

The first official version of the European quality assurance scheme for breast cancer services is now available on the European Commission web hub.

Cancer detection rates were 6·4 per 1,000 screened in the group that underwent mammography with AI use compared to five per 1 ...

Revolutionary AI breast cancer screening trial launches across 30 UK sites, promising to tackle radiologist shortages and speed up diagnosis for 700,000 women.